| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Martha J Demski is Director at ADMA and has filed Form 4s across 3 companies. Martha J Demski's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $717K at current prices.
The biggest single holding is ADMA (~$629K) as Director. Net of sales, the ADMA filings show accumulation of 4,200 shares.
Martha J Demski has 25 Form 4 filings on record from June 2015 to July 2026, across 4 companies: Director at Alpha Teknova (TKNO), 2023–2026; Director at Equillium (EQ), 2019–2026; Director at Adma Biologics (ADMA), 2020–2023, and 1 more.
The 39 reported transactions were 25 option or other derivative awards, 4 stock awards, 4 dispositions back to the company and 2 other transactions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $11K and 1 sale worth about $41K.
The largest open-market purchase was 2,000 shares of ADMA at an average $2.88 on August 13, 2020, about $6K.
The only open-market sale was 8,000 shares of TKNO at an average $5.06 on June 27, 2025, about $41K.